Company news
Greenwich Lifesciences, Inc. (NASDAQ:GLSI) news
Greenwich Lifesciences, Inc. news releases on 6ix. Latest, Aug 10, 2026: Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
Press releases & updates
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
August 10, 2026
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
July 22, 2026
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
July 20, 2026
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
July 16, 2026
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
July 9, 2026
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
June 1, 2026
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
May 22, 2026
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
April 30, 2026
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
April 23, 2026
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
April 22, 2026
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
April 20, 2026
Greenwich LifeSciences Provides Update on Financing Strategy
April 13, 2026
Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential
April 6, 2026
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01
March 18, 2026
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
March 17, 2026
Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01
March 16, 2026
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01
March 15, 2026
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01
March 2, 2026
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026
February 23, 2026
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
January 27, 2026
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01
January 22, 2026
Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026
December 29, 2025
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
December 22, 2025
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
December 15, 2025
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
December 8, 2025
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
December 7, 2025
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date
December 3, 2025
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
October 9, 2025
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
October 2, 2025
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
September 30, 2025
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland
September 18, 2025
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
September 10, 2025
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
August 19, 2025
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
August 13, 2025
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
August 11, 2025
Greenwich LifeSciences Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
June 27, 2025
Greenwich LifeSciences Provides Global Update on FLAMINGO-01
April 3, 2025
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
April 2, 2025
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
March 27, 2025
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
March 17, 2025
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
February 9, 2025
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
January 28, 2025
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
January 26, 2025
Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01
January 22, 2025
Greenwich LifeSciences Provides Update on Commercial Manufacturing
January 21, 2025
Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01
January 13, 2025
Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France
January 12, 2025
Greenwich LifeSciences Partners with GIM in Italy
November 25, 2024
Greenwich LifeSciences Provides Update on Corporate Events
November 17, 2024
Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain
July 31, 2024